Back to search

Article

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

2023-12-28

Abstract excerpt

<h4>Background: </h4> The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for treatment efficacy. The aim of this study is to optimize PDO drug screening methods for correlation with patient response and explore the potential to predict responses to s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b1557721-0897-5d65-9739-73b3dc761d6b
DOI
10.21203/rs.3.rs-3794312/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient responseDOI 10.21203/rs.3.rs-3794312/v1
“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”Semantic proximity
Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity
Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response PhenotypesSemantic proximity
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.Semantic proximity
Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity
SCOPE: Integrating Organoid Screening and Clinical Variables Through Machine Learning for Cancer Trial Outcome PredictionSemantic proximity
BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.Semantic proximity
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitorsSemantic proximity
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity
Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistanceSemantic proximity
Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technologySemantic proximity
Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical ResponsesSemantic proximity
Select a neighboring publication to make it the new centre.